Drugs / PG-102(MG12)
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06309667 | Mar 2024 → Feb 2025 | obesity disorder | ProGen. Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07677891 | Oct 2026 → May 2027 expected | type 2 diabetes mellitus | ProGen. Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PG-102(MG12) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06309667 ↗ |
| Known as | PG-102 | “PG-102 is a potency-optimized bispecific Fc fusion protein targeting GLP-1 and GLP-2 receptors.” PMID 41876542 ↗ Mar 2026 |
| Modality | Protein / enzyme biologic | “PG-102 is a potency-optimized bispecific Fc fusion protein targeting GLP-1 and GLP-2 receptors.” PMID 41876542 ↗ Mar 2026 |
| Route | Subcutaneous | “following subcutaneous injections of PG-102(MG12) in healthy adult participants.” NCT06309667 ↗ |